Gingko Biloba Doesn’t Prevent Dementia
Taking ginkgo biloba , an herbal supplement, did not lower the risk of developing dementia. A recent study gave ginkgo biloba to older people with memory problems for five years.
NFL Players’ Brain Disease Risk Triple
The NFL season kicked off September 5. The same day, the U.S. Centers for Disease Control and Prevention (CDC) issued a special report about NFL players' deaths from brain diseases.
Dementia Brain Changes Show up Early
Memory problems are the first symptoms of dementia. New research shows that changes in the brain may show up as much as 10 years before memory symptoms.
Care Giver Coping May Affect Dementia
Caring for a loved one with dementia can be stressful. The way you cope with that stress may affect the way your loved one’s dementia changes over time.
Fitness Now Improves Life Later
Higher fitness levels bring lots of benefits to individuals in the now. It helps keep away illnesses and makes the body strong. And fitness also has an effect way down the road by adding years to life, but its quality had been in question.
Alzheimer’s Drug Struggles in Trials
Solanezumab is a new drug being tested with Alzheimer’s Disease (AD) patients. The test results indicate that it failed to improve memory and daily function, but the drug did slow the rate of memory loss.
Is Delirium Different Than Dementia?
When a person is confused or has memory problems for a very short time it is called delirium. It may raise the risk of dementia, which is a longer term issue.
Hormones Linked to Improved Thinking
Drugs are often used to help memory in people with dementia. New research is looking into ways a hormone may help people with dementia too. A recent study found that taking a hormone, which is a natural part of the body’s function, improved thinking skills for elderly people.
Obesity May Speed-Up Cognitive Decline
Keeping a healthy weight has many benefits. Recent research suggests that it may also help keep memory sharp as you age. A recent study looked at people’s weight and other health problems, like high blood pressure or high cholesterol.
Clinical Endpoints Not Met In Alzheimer Drug Study
Pfizer Inc. announced that the co-primary clinical endpoints, change in cognitive and functional performance compared to a placebo, were not met in the Janssen Alzheimer Immunotherapy R&D LLC (Janssen AI)-led Phase 3 trial of intravenous (IV) bapineuzumab in patients with mild-to-moderate Alzheimer’s disease who do not carry the ApoE4 (apolipoprotein E epsilon 4) genotype (Study 301). Pfizer and Janssen AI are partners in the Alzheimer’s Immunotherapy Program (AIP).